Drugs / UDI-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04873752 | Jun 2021 → Jul 2023 | cerebral palsy, periventricular leukomalacia | Rohto Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UDI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04873752 ↗ |
| Modality | Cell therapy | “umbilical cord derived mesenchymal stromal cells (UC-MSCs) are administered” NCT04873752 ↗ |
| Route | Intravenous | “administered intravenously” NCT04873752 ↗ |